

EFFECT OF BARIATRIC SURGERY ON REGRESSION OF ENDOMETRIAL CANCER AS PART OF FERTILITY SPARING MANAGEMENT


Joshua SH Lim¹, Amadora Choo¹, Jiwei Guo¹, Annalisa Ya-Lyn Ng¹, Jinlin Lin¹

¹ Department of Surgery, Changi General Hospital, Singapore


The authors of this study have no potential conflict of interest to report.

Background

- Endometrial cancer (EC) is the 2nd most common gynaecological cancer globally¹
- Standard treatment for early EC: total hysterectomy with bilateral salpingo-oophorectomy (THBSO)
- Fertility sparing treatment (FST): endocrine / hormonal therapy



Rising incidence of early onset EC²



Delayed childbearing age³

Mechanistic Pathways Linking Obesity to Endometrial Cancer





Fig 1. Effects of obesity on endometrial proliferation and tumorigenesis. Obesity contributes to the increased risk of endometrial cancer in the postmenopausal uterus by a variety of mechanisms. Increased adiposity increases aromatase activity, which leads to the conversion of androgens to estrogens, to directly promote endometrial proliferation and transcription of proproliferative genes. The chronic inflammation associated with visceral adiposity is mediated by proinflammatory adipokines and leads to hyperinsulinemia, increases in insulin-like growth factor 1 (IGF1), and hyperglycemia, which fuel endometrial proliferation. A concurrent decrease in anti-inflammatory cytokines is also observed. Inflammation and an increase in estrogen metabolites further contribute to DNA damage and genetic instability. Finally, stem cells can be recruited from adipose tissue, where they contribute to a supportive tumor microenvironment. ER, estrogen receptor; IGF1R, insulin-like growth factor 1 receptor; IR, insulin receptor; IRS, insulin receptor substrate; mTOR, mammalian target of rapamycin. (Illustration created by Suety Kwan).

4. Michaela A. Onstad et al. Addressing the role of obesity in endometrial cancer risk, prevention and treatment. *J Clin Oncol* 2016 34:4225-4230.



Endometrial Cancer

(Increased prevalence⁵) of
Obesity

Bariatric Surgery (BS)
Treatment

Does bariatric surgery have a role in the fertility sparing treatment (FST) of endometrial cancer (EC)?

Aims and Methods

- Observational analysis of early regression and continued remission of EC in tandem with sustained weight reduction for all patients on FST who also underwent BS
- Single centre, retrospective case series from Jan 2021- Dec 2023



Inclusion Criteria

EC on fertility sparing treatment AND BMI>37.5kg/m² OR BMI>32.5kg/m² with related comorbidities

Females of reproductive age who wished to preserve fertility

Histologically proven G1 endometrial cancer without myometrial invasion/lymph node involvement/metastasis

Exclusion Criteria

Patients who underwent THBSO for EC treatment


Patients who did not undergo BS

Patients on fertility sparing treatment whose EC showed regression before BS

Genetic syndromes (eg. Lynch syndrome)

Methods

- Protocol for fertility sparing treatment for patients with early endometrial cancer.



Results


Table 1. Patient Characteristics

Patient	Age (years)	Comorbidities	Pre-op Weight (kg)	Pre-Op BMI (kg/m ²)
1	32	Asthma, DM	106.5	40.65
2	37	DM, Hypertension, Hyperlipidemia	113.1	40.10
3	27	Nil	89.8	38.80
4	35	Hyperlipidemia	106.4	40.00
5	29	Nil	131.9	44.10
6	29	DM, polycystic ovary syndrome	98.3	41.50
7	34	Nil	103.0	40.70

Abbreviations: diabetes mellitus (DM)

Results

Weight Loss Percentage After Bariatric Surgery



Results

Table 2. Outcomes After BS

Patient	Age (years)	Date of BS	Length of follow up (months)	Time to EC regression (months)	Remission	Outcomes
1	32	July 2021	37	1	N	IVF-NVD Apr 2023
2	37	July 2021	37	2	Y	IVF-unsuccessful
3	27	December 2021	32	6	Y	-
4	35	April 2022	28	5	Y	Natural-LSCS Jun 24
5	29	November 2022	20	2	Y	IVF-EDD Feb 2025
6	29	February 2023	18	NA	N	-
7	34	November 2023	9	4	Y	-

Abbreviations:

IVF-in-vitro fertilization

EDD-estimated date of delivery

NVD-normal vaginal delivery

LSCS-lower segment caesarean section

Benefits for Patients with EC on FST undergoing BS

General Health	Oncology	Reproductive Health	Antenatal Health
<ul style="list-style-type: none"> • Significant lasting weight loss • Improvement in obesity-related comorbidities • Increased life expectancy • Improvement in quality of life and psychological health 	<ul style="list-style-type: none"> • Potentially help in cancer regression as part of fertility sparing therapy • Improved outcomes and reduced risks during definitive surgery (THBSO) 	<ul style="list-style-type: none"> • Improved fertility rates • Improved success rates from Assisted Reproductive Techniques (ART) 	<ul style="list-style-type: none"> • Reduced pregnancy-related complications e.g. Gestation Diabetes Mellitus (GDM) and Pre-Eclampsia • Reduced rates of miscarriage • Reduced perinatal complications

Limitations

- Retrospective study
- No control group
- Small group of patients
- Short follow up time

Conclusion

- BS has the potential to be an integral part of fertility sparing treatment
- Such patients should be managed in a multi-disciplinary team including gynae-oncology and bariatric specialists.
- Further prospective studies with a longer follow up period are necessary.

Acknowledgement

The authors would like to thank the Department of Gynae-Oncology and Department of Reproductive Medicine, Division of O&G, Kandang Kerbau Women's and Children's Hospital, Singapore.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209-249.
2. Liu L, Habeshian TS, Zhang J, et al. Differential trends in rising endometrial cancer incidence by age, race, and ethnicity. *JNCI Cancer Spectr.* 2023;7(1):pkad001.
3. Martinez GM, Daniels K. Fertility of men and women aged 15–49 in the United States: National Survey of Family Growth, 2015–2019. National Health Statistics Reports; no 179. Hyattsville, MD: National Center for Health Statistics. 2023.
4. Onstad MA, Schmandt RE, Lu KH. Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment. *J Clin Oncol.* 2016;34(35):4225-4230.
5. Swinburn BA, Kraak VI, Allender S, et al. The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report [published correction appears in Lancet. 2019 Feb 23;393(10173):746.